• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Statistical reporting of clinical pharmacology research.临床药理学研究的统计报告
Br J Clin Pharmacol. 2017 Jun;83(6):1159-1162. doi: 10.1111/bcp.13254. Epub 2017 Mar 21.
2
Practical and statistical considerations on simultaneous global drug development.同步全球药物研发的实践与统计学考量
J Biopharm Stat. 2012 Sep;22(5):1074-7. doi: 10.1080/10543406.2012.701588.
3
Approaches to simultaneous analysis of frequency and severity of symptoms.症状频率和严重程度同步分析方法。
Clin Pharmacol Ther. 2010 Aug;88(2):255-9. doi: 10.1038/clpt.2010.118. Epub 2010 Jul 7.
4
Design and sample size considerations for simultaneous global drug development program.同步全球药物研发计划的设计与样本量考量
J Biopharm Stat. 2012 Sep;22(5):1060-73. doi: 10.1080/10543406.2012.701587.
5
Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions.药效学建模的统计方法:动机、方法及误解
Cancer Chemother Pharmacol. 1993;33(1):1-9. doi: 10.1007/BF00686015.
6
Utilisation of human pharmacology studies with biomarkers for new drug applications in Japan.在日本将生物标志物用于新药申请的人体药理学研究的应用情况
Drugs R D. 2005;6(1):21-34. doi: 10.2165/00126839-200506010-00003.
7
Optimal design of pharmacokinetic studies.药代动力学研究的优化设计。
Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):250-5. doi: 10.1111/j.1742-7843.2009.00533.x. Epub 2010 Jan 20.
8
Biostatistics and pharmacometrics: quantitative sciences to propel drug development forward.生物统计学与药理计量学:推动药物研发前进的定量科学。
Clin Pharmacol Ther. 2010 Aug;88(2):141-4. doi: 10.1038/clpt.2010.136.
9
[Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].[加速从临床前到临床阶段开发进程的临床药理学方面/首次交流:临床药理学的贡献]
Arzneimittelforschung. 2004;54(5):251-8. doi: 10.1055/s-0031-1296967.
10
Improving productivity with model-based drug development: an enterprise perspective.基于模型的药物研发提高生产力:企业视角
Clin Pharmacol Ther. 2010 Aug;88(2):263-8. doi: 10.1038/clpt.2010.117. Epub 2010 Jun 30.

引用本文的文献

1
Warfarin dose requirement in patients having severe thrombosis or thrombophilia.严重血栓形成或血栓形成倾向患者的华法林剂量需求。
Br J Clin Pharmacol. 2019 Aug;85(8):1684-1691. doi: 10.1111/bcp.13948. Epub 2019 Jun 17.
2
Cefuroxime plasma and tissue concentrations in patients undergoing elective cardiac surgery: Continuous vs bolus application. A pilot study.择期心脏手术患者头孢呋辛的血浆和组织浓度:连续输注与推注给药。一项初步研究。
Br J Clin Pharmacol. 2019 Apr;85(4):818-826. doi: 10.1111/bcp.13865. Epub 2019 Feb 13.
3
Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomized controlled VaSera trial.在因子设计、双盲、随机对照 VaSera 试验中,研究了 6 个月饮食硝酸盐和螺内酯对高血压伴/有 2 型糖尿病风险患者的心脏影响。
Br J Clin Pharmacol. 2019 Jan;85(1):169-180. doi: 10.1111/bcp.13783. Epub 2018 Nov 13.

本文引用的文献

1
A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio ) in cardiac surgery: the REVAKI-1 study.一项旨在确定西地那非(瑞伐他汀)在心脏手术中的药代动力学特征、安全性和耐受性的I期研究:REVAKI-1研究。
Br J Clin Pharmacol. 2017 Apr;83(4):709-720. doi: 10.1111/bcp.13162. Epub 2016 Dec 1.
2
An investigation of the false discovery rate and the misinterpretation of p-values.对错误发现率和p值误读的调查。
R Soc Open Sci. 2014 Nov 19;1(3):140216. doi: 10.1098/rsos.140216. eCollection 2014 Nov.
3
Common misconceptions about data analysis and statistics.关于数据分析和统计学的常见误解。
Br J Pharmacol. 2015 Apr;172(8):2126-32. doi: 10.1111/bph.12884. Epub 2014 Sep 26.
4
Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.群体建模、模拟及基于模型的药物研发基础概念——第2部分:药代动力学建模方法介绍
CPT Pharmacometrics Syst Pharmacol. 2013 Apr 17;2(4):e38. doi: 10.1038/psp.2013.14.
5
To test or not to test: Preliminary assessment of normality when comparing two independent samples.是否进行检验:比较两个独立样本时对正态性的初步评估。
BMC Med Res Methodol. 2012 Jun 19;12:81. doi: 10.1186/1471-2288-12-81.
6
The empirical coverage of confidence intervals: point estimates and confidence intervals for confidence levels.置信区间的经验覆盖范围:置信水平的点估计和置信区间
Biom J. 2012 Jul;54(4):537-51. doi: 10.1002/bimj.201100134. Epub 2012 May 23.
7
Statistical guide for clinical pharmacology & therapeutics.临床药理学与治疗学统计指南
Clin Pharmacol Ther. 2010 Aug;88(2):150-2. doi: 10.1038/clpt.2010.113. Epub 2010 Jun 30.
8
Why are pharmacokinetic data summarized by arithmetic means?为什么药代动力学数据要用算术平均值来汇总?
J Biopharm Stat. 2000 Feb;10(1):55-71. doi: 10.1081/BIP-100101013.
9
Learning versus confirming in clinical drug development.临床药物研发中的学习与验证
Clin Pharmacol Ther. 1997 Mar;61(3):275-91. doi: 10.1016/S0009-9236(97)90160-0.

临床药理学研究的统计报告

Statistical reporting of clinical pharmacology research.

作者信息

Ring Arne, Schall Robert, Loke Yoon K, Day Simon

机构信息

University of the Free State, Bloemfontein, South Africa.

medac GmbH, Wedel, Germany.

出版信息

Br J Clin Pharmacol. 2017 Jun;83(6):1159-1162. doi: 10.1111/bcp.13254. Epub 2017 Mar 21.

DOI:10.1111/bcp.13254
PMID:28321897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5427231/
Abstract

Research in clinical pharmacology covers a wide range of experiments, trials and investigations: clinical trials, systematic reviews and meta-analyses of drug usage after market approval, the investigation of pharmacokinetic-pharmacodynamic relationships, the search for mechanisms of action or for potential signals for efficacy and safety using biomarkers. Often these investigations are exploratory in nature, which has implications for the way the data should be analysed and presented. Here we summarize some of the statistical issues that are of particular importance in clinical pharmacology research.

摘要

临床药理学研究涵盖广泛的实验、试验和调查:临床试验、药品上市后使用情况的系统评价和荟萃分析、药代动力学-药效学关系的研究、利用生物标志物寻找作用机制或疗效及安全性的潜在信号。这些研究往往具有探索性,这对数据的分析和呈现方式具有影响。在此,我们总结一些在临床药理学研究中特别重要的统计学问题。